SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001867096-23-000003
Filing Date
2023-01-05
Accepted
2023-01-05 07:04:08
Documents
15
Period of Report
2023-01-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xers-20230105.htm   iXBRL 8-K 35953
2 EX-99.1 pressreleaseissuedbyxerisb.htm EX-99.1 11265
7 image_0a.jpg GRAPHIC 18252
  Complete submission text file 0001867096-23-000003.txt   249898

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20230105.xsd EX-101.SCH 2153
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xers-20230105_def.xml EX-101.DEF 15449
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20230105_lab.xml EX-101.LAB 29866
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20230105_pre.xml EX-101.PRE 16118
9 EXTRACTED XBRL INSTANCE DOCUMENT xers-20230105_htm.xml XML 11554
Mailing Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601
Business Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601 844-445-5704
Xeris Biopharma Holdings, Inc. (Filer) CIK: 0001867096 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40880 | Film No.: 23509709
SIC: 2834 Pharmaceutical Preparations